#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4704	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2613	533.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1769	1769	C	719	C,A	597,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7046	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4049	520.3	0	.	n	.	0	T695C	SNP	695	695	T	1342	1342	C	546	C,T	448,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7046	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4049	520.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1984	1984	A	620	A,C	528,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7046	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4049	520.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2618	2618	C	609	C,T,A	521,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7046	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4049	520.3	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3244	3244	T	576	T,A	494,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7046	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4049	520.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2692	2692	A	620	A	524	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	718	folP	852	852	100.0	folP.l6.c4.ctg.1	1957	109.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1249	1251	AGC	160;162;161	A;G;C	140;142;142	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1598	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3887	123.2	1	SNP	p	S91F	0	.	.	271	273	TCC	809	811	TCC	141;141;141	T;C,T;C	115;119,1;115	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1598	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3887	123.2	1	SNP	p	D95N	0	.	.	283	285	GAC	821	823	GAC	137;136;137	G;A,G;C	113;112,1;121	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1598	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3887	123.2	1	SNP	p	D95G	0	.	.	283	285	GAC	821	823	GAC	137;136;137	G;A,G;C	113;112,1;121	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	816	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1744	140.0	1	SNP	p	G45D	1	.	.	133	135	GAC	746	748	GAC	211;209;211	G;A;C	186;186;188	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	264	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	1104	71.3	0	.	n	.	0	G15A	SNP	15	15	G	312	312	A	59	A	50	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1574	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3509	134.2	1	SNP	p	D86N	0	.	.	256	258	GAC	850	852	GAC	167;167;167	G;A,T;C	142;141,1;141	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1574	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3509	134.2	1	SNP	p	S87I	0	.	.	259	261	AGT	853	855	AGT	167;166;166	A,C;G;T,A	137,1;142;139,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1574	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3509	134.2	1	SNP	p	S87R	0	.	.	259	261	AGT	853	855	AGT	167;166;166	A,C;G;T,A	137,1;142;139,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1574	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3509	134.2	1	SNP	p	S87W	0	.	.	259	261	AGT	853	855	AGT	167;166;166	A,C;G;T,A	137,1;142;139,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1574	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3509	134.2	1	SNP	p	S88P	0	.	.	262	264	TCC	856	858	TCC	165;165;167	T;C,T;C	139;143,1;145	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1432	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3188	134.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1876	1878	GGC	174;172;173	G,T;G;C	144,1;143;144	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.47.001	penA.47.001	1	1	27	1288	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2745	140.4	1	SNP	p	A311V	0	.	.	931	933	GCC	1418	1420	GCC	178;178;178	G;C;C	156;149;156	penA.47.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1288	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2745	140.4	1	SNP	p	I312M	1	.	.	934	936	ATG	1421	1423	ATG	176;176;176	A;T;G	155;153;153	penA.47.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1288	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2745	140.4	1	SNP	p	T316P	0	.	.	946	948	ACC	1433	1435	ACC	181;181;181	A;C;C	152;153;154	penA.47.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1288	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2745	140.4	1	SNP	p	V316T	1	.	.	946	948	ACC	1433	1435	ACC	181;181;181	A;C;C	152;153;154	penA.47.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1288	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2745	140.4	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1934	1936	ACC	186;186;186	A;C;C,A	153;149;147,1	penA.47.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1288	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2745	140.4	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1988	1990	GCG	197;196;196	G,C;C,G;G,T	156,1;156,1;156,1	penA.47.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1288	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2745	140.4	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1988	1990	GCG	197;196;196	G,C;C,G;G,T	156,1;156,1;156,1	penA.47.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1288	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2745	140.4	1	SNP	p	G542S	0	.	.	1624	1626	GGC	2111	2113	GGC	185;184;185	G;G;C	154;152;154	penA.47.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1288	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2745	140.4	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2120	2122	GGC	191;192;192	G;G;C	157;160;159	penA.47.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.47.001	penA.47.001	1	1	27	1288	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2745	140.4	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2138	2140	CCG	194;195;195	C;C,G;G,A	159;157,1;157,1	penA.47.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1526	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3502	130.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	864	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2342	110.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	893	893	C	131	C	115	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	824	porB1b	1035	1035	98.19	porB1b.l15.c4.ctg.1	1844	130.9	0	.	p	.	0	H39L	NONSYN	115	117	CAT	641	643	CTT	184;185;186	C;T,A;T	152;151,1;155	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	824	porB1b	1035	1035	98.19	porB1b.l15.c4.ctg.1	1844	130.9	0	.	p	.	0	E48K	NONSYN	142	144	GAA	668	670	AAA	183;178;178	A,G;A;A	152,1;155;153	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	824	porB1b	1035	1035	98.19	porB1b.l15.c4.ctg.1	1844	130.9	0	.	p	.	0	R143G	NONSYN	427	429	AGA	953	955	GGA	159;159;159	G;G,A;A	137;137,1;139	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	824	porB1b	1035	1035	98.19	porB1b.l15.c4.ctg.1	1844	130.9	0	.	p	.	0	S175T	NONSYN	523	525	TCA	1049	1051	ACA	188;186;187	A;C;A	158;158;160	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	824	porB1b	1035	1035	98.19	porB1b.l15.c4.ctg.1	1844	130.9	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1157	1157	T	174	T	150	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	824	porB1b	1035	1035	98.19	porB1b.l15.c4.ctg.1	1844	130.9	1	SNP	p	G120K	0	.	.	358	360	GGT	884	886	GGT	186;184;183	G;G;T	151;150;147	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	824	porB1b	1035	1035	98.19	porB1b.l15.c4.ctg.1	1844	130.9	1	SNP	p	A121D	0	.	.	361	363	GCC	887	889	GCC	184;183;183	GCC,GC;C;CAA,CA	149,1;144;152,1	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	824	porB1b	1035	1035	98.19	porB1b.l15.c4.ctg.1	1844	130.9	1	SNP	p	A121N	0	.	.	361	363	GCC	887	889	GCC	184;183;183	GCC,GC;C;CAA,CA	149,1;144;152,1	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3150	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5225	180.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2142	2144	AAT	187;188;187	A,C;A;T	156,1;153;155	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	478	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1242	113.6	1	SNP	p	V57M	1	.	.	169	171	ATG	622	624	ATG	186;188;188	A;T;G	149;153;151	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
